Scarica l'app Stockscreener
3.03
0.33%
-0.01
Dopo l'orario di chiusura:
3.08
0.05
+1.65%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABCL Giù?
Forum
Previsione
Abcellera Biologics Inc Borsa (ABCL) Ultime notizie
AbCellera Biologics Inc (ABCL) Misses Q4 2025 Earnings Estimates — EPS $-0.19 vs $-0.16 Expected - AlphaStreet News
AbCellera Biologics Faces Stock Volatility Amid Strategic Decisions - timothysykes.com
AbCellera Biologics Inc (ABCL) down 23% since Q3 2025 results - MSN
Is AbCellera Biologics Inc affected by consumer sentimentJuly 2025 Recap & Real-Time Volume Spike Alerts - baoquankhu1.vn
AbCellera Biologics Inc. (NASDAQ:ABCL) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
AbCellera Biologics (ABCL) Projected to Post Earnings on Tuesday - MarketBeat
Aug Mood: Is AbCellera Biologics Inc a potential multi baggerJuly 2025 Rallies & Expert-Curated Trade Recommendations - baoquankhu1.vn
AbCellera Biologics (NASDAQ:ABCL) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Trading Up 8.3%Still a Buy? - MarketBeat
AbCellera Biologics Inc. (ABCL) Stock Analysis: A Biotech With A 234% Potential Upside - DirectorsTalk Interviews
How resilient is AbCellera Biologics Inc. stock in market downturnsJuly 2025 Weekly Recap & Daily Entry Point Alerts - mfd.ru
State of Michigan Retirement System Acquires 350,775 Shares of AbCellera Biologics Inc. $ABCL - MarketBeat
Is AbCellera’s Biotech Platform Setting New Standards for Pharmaceutical Innovation - Kalkine Media
Painful Week for Individual Investors Invested in AbCellera Biologics Inc. (NASDAQ:ABCL) After 10% Drop, Institutions Also Suffered Losses - 富途牛牛
Travel Stocks: Is Lifeway Foods Inc forming a double bottom2025 Analyst Calls & Daily Chart Pattern Signals - baoquankhu1.vn
AbCellera to Present at Upcoming Investor Conferences in March and April 2026 - Investing News Network
How AbCellera Biologics Inc. stock trades before earnings2025 Earnings Surprises & Stock Timing and Entry Methods - mfd.ru
Is AbCellera (ABCL) Trading Its Platform Identity For Higher-Stakes Clinical Ambitions? - Sahm
Short sales on the TSX: What bearish investors are betting against - The Globe and Mail
Will AbCellera Biologics Inc. stock maintain growth story2025 Pullback Review & Long-Term Growth Stock Strategies - mfd.ru
OpenAI considers backing AI-led drug discovery firms: report - Seeking Alpha
AbCellera Biologics Inc. (ABCL): A Bull Case Theory - Insider Monkey
What does Wall Street think about AbCellera Biologics Inc. (ABCL)? - MSN
AbCellera’s ABCL635 Phase 2 Start Highlights Menopause Focus And Valuation Gap - Yahoo Finance
AbCellera Biologics (ABCL) Valuation Check After Mixed Long Term Shareholder Returns - Yahoo Finance
AbCellera Advances ABCL635 Menopause Candidate As Shares Trade Below Targets - Sahm
Reassessing AbCellera Biologics (ABCL) After A Sharp 16.8% Weekly Share Price Drop - Yahoo Finance
What Does Wall Street Think About AbCellera Biologics Inc. (ABCL)? - Insider Monkey
Exit Recap: Why is AbCellera Biologics Inc stock going downJuly 2025 Sector Moves & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Can AbCellera Biologics Inc disrupt its industry2025 Winners & Losers & Free High Return Stock Watch Alerts - baoquankhu1.vn
Strategic Moves Shape ABCL’s Market Position - StocksToTrade
AbCellera’s Market Moves: Key Developments - timothysykes.com
AbCellera Biologics Inc. (NASDAQ:ABCL) Given Average Rating of "Hold" by Brokerages - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Trading Down 6.1%Here's Why - MarketBeat
Is AbCellera Biologics Inc a top pick in the sectorPortfolio Value Summary & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
AbCellera Biologics Inc. (ABCL) Stock Analysis: Exploring a Promising 111.93% Potential Upside - DirectorsTalk Interviews
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026 - PharmiWeb.com
AbCellera Biologics (NASDAQ:ABCL) Trading Up 11.6%Here's Why - MarketBeat
A Look At AbCellera Biologics (ABCL) Valuation After ABCL635 Advances Into Phase 2 Trial - Sahm
AbCellera Biologics (NASDAQ:ABCL) Stock Rating Lowered by Wall Street Zen - MarketBeat
Why AbCellera Biologics Inc. stock could rally in 2025High Dividend Yield Stocks & Invest Like A Pro - bollywoodhelpline.com
Is AbCellera (ABCL) Quietly Recasting Its Platform As A Menopause-Focused Drug Developer? - simplywall.st
Aug Reactions: What is the implied volatility of Sonida Senior Living IncMarket Movers & Weekly Hot Stock Watchlists - baoquankhu1.vn
Citizens Financial Group Inc. RI Acquires Shares of 261,890 AbCellera Biologics Inc. $ABCL - MarketBeat
AbCellera Biologics Pivots to Internal Pipeline at JPMorgan, Teases Key Milestones for 2026 - Yahoo Finance
AbCellera Biologics Inc Doses First Patients in Phase 2 Trial for ABCL635 - TradingView — Track All Markets
AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 - Investing News Network
AbCellera Biologics (NASDAQ:ABCL) Shares Down 5.6%Should You Sell? - MarketBeat
AbCellera begins phase 2 trial of non-hormonal menopause treatment By Investing.com - Investing.com Nigeria
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause - BioSpace
AbCellera begins phase 2 trial of non-hormonal menopause treatment - Investing.com
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL6 - PharmiWeb.com
AbCellera (ABCL) Advances Clinical Trial for Menopause Treatment - GuruFocus
AbCellera Biologics (NASDAQ:ABCL) Shares Gap Up on Analyst Upgrade - MarketBeat
2.25%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):